Journal of drug targeting,
Journal Year:
2024,
Volume and Issue:
32(7), P. 770 - 784
Published: May 8, 2024
The
World
Health
Organization
(WHO)
reported
that
of
all
the
non-communicable
diseases,
cancer
is
considered
second
cause
death
worldwide.
This
has
driven
big
pharma
companies
to
prioritize
anticancer
products
in
their
pipeline.
In
addition,
research
focused
on
exploration
new
molecules
and
design
suitable
dosage
forms
achieve
effective
drug
delivery
tumor
site.
Nanotechnology
a
valuable
tool
build
nano
systems
with
controlled
targeted
release
properties.
Nanoparticles
can
be
fabricated
by
robust,
scalable
economic
techniques
using
various
polymers.
Moreover,
specific
functional
groups
introduced
surface
nanoparticles
enabling
targeting
tissue;
besides,
they
exhibit
versatile
patterns
according
rate
polymer
degradation.
review
outlines
processes
advances
functionalization
employed
for
treatment
breast
cancer.
therapeutic
molecules,
polymers
used
fabricate
nanoparticles,
prepare
have
been
reviewed
focus
functionalize
these
ligands
target
different
types
Coatings,
Journal Year:
2023,
Volume and Issue:
13(9), P. 1660 - 1660
Published: Sept. 21, 2023
This
review
focuses
on
the
surface
modification
of
metallic
nanoparticles
for
targeted
drug
delivery.
Metallic
nanoparticles,
owing
to
their
unique
size,
stability,
and
payload
capacity,
have
emerged
as
promising
carriers.
However,
application
necessitates
enable
precise
targeting.
Various
strategies,
such
polymer
coating
methods,
use
functional
groups,
bio-conjugation
with
targeting
ligands,
are
explored.
The
also
discusses
selection
ligands
based
target
receptors,
active
passive
approaches,
stimuli-responsive
It
further
delves
into
challenges
translating
these
strategies
clinical
settings,
including
scalability,
toxicity,
regulatory
hurdles.
is
a
avenue
coating,
functionalization
specific
bioconjugation
been
explored
enhance
therapeutic
potential
nanoparticles.
in
translation,
continuous
advancements
nanoparticle
synthesis,
techniques
offer
positive
outlook
future
systems.
Despite
delivery,
there
several
that
need
be
addressed
successful
translation.
These
include
scalable
fabrication
toxicity
concerns,
synthesis
expected
overcome
near
future.
Pharmaceutics,
Journal Year:
2023,
Volume and Issue:
15(11), P. 2620 - 2620
Published: Nov. 12, 2023
Colorectal
cancer
(CRC)
is
one
of
the
deadliest
malignancies
in
US,
ranking
fourth
after
lung,
prostate,
and
breast
cancers,
respectively,
general
populations.
It
continues
to
be
a
menace,
incidence
has
been
projected
more
than
double
by
2035,
especially
underdeveloped
countries.
This
review
seeks
provide
some
insights
into
disease
progression,
currently
available
treatment
options
their
challenges,
future
perspectives.
Searches
were
conducted
PubMed
search
engine
university’s
online
library.
The
keywords
“Colorectal
Cancer”
AND
“disease
process”
OR
mechanisms”
“Current
Treatment”
“Prospects”.
Selection
criteria
original
articles
published
primarily
during
period
2013
through
2023.
Abstracts,
books
documents,
reviews/systematic
reviews
filtered
out.
Of
over
490
thousand
returned,
only
about
800
met
preliminary
selection
criteria,
200
reviewed
detail,
but
191
final
criteria.
Fifty-one
other
used
due
cross-referencing.
Although
recently
considered
lifestyle,
CRC
appears
rising
countries
with
low,
low–medium,
medium
social
demographic
indices.
can
affect
all
parts
colon
rectum
fatal
poor
outcomes
when
it
right-sided.
progression
usually
takes
between
7–10
years
asymptomatic,
making
early
detection
diagnosis
difficult.
tumor
microenvironment
made
up
different
types
cells
interacting
each
promote
growth
proliferation
cells.
Significant
advancement
colorectal
cancer.
Notable
approaches
include
surgery,
chemotherapy,
radiation
therapy,
cryotherapy.
Chemotherapy,
including
5-fluorouracil,
irinotecan,
oxaliplatin,
leucovorin,
plays
significant
role
management
that
diagnosed
at
advanced
stages.
Two
classes
monoclonal
antibody
therapies
have
approved
FDA
for
cancer:
vascular
endothelial
factor
(VEGF)
inhibitor,
e.g.,
bevacizumab
(Avastin®),
epidermal
receptor
(EGFR)
cetuximab
(Erbitux®)
panitumumab
(Verbitix®).
However,
many
problems
are
still
being
experienced
these
treatments,
mainly
off-target
effects,
toxic
side
associated
therapeutic
failures
small
molecular
drugs
rapid
loss
efficacy
mAb
therapies.
Other
novel
delivery
strategies
continue
investigated,
ligand-based
targeting
International Journal of Molecular Sciences,
Journal Year:
2023,
Volume and Issue:
24(12), P. 10082 - 10082
Published: June 13, 2023
Over
the
past
few
decades,
enhanced
permeability
and
retention
(EPR)
effect
of
nanomedicine
has
been
a
crucial
phenomenon
in
targeted
cancer
therapy.
Specifically,
understanding
EPR
significant
aspect
delivering
anticancer
agents
efficiently
to
tumors.
Although
therapeutic
demonstrated
experimental
models
using
mouse
xenografts,
clinical
translation
faces
several
challenges
due
dense
extracellular
matrix
(ECM),
high
interstitial
fluid
pressure
(IFP)
levels,
other
factors
that
arise
from
tumor
heterogeneity
complexity.
Therefore,
mechanism
clinics
is
essential
overcome
hurdles
nanomedicine.
This
paper
introduces
basic
nanomedicine,
recently
discussed
various
strategies
recent
limitations
expected
patients’
microenvironments.
Biomedical Physics & Engineering Express,
Journal Year:
2023,
Volume and Issue:
9(5), P. 052002 - 052002
Published: Aug. 7, 2023
Abstract
Nanomedicine
and
nano-delivery
systems
hold
unlimited
potential
in
the
developing
sciences,
where
nanoscale
carriers
are
employed
to
efficiently
deliver
therapeutic
drugs
at
specifically
targeted
sites
a
controlled
manner,
imparting
several
advantages
concerning
improved
efficacy
minimizing
adverse
drug
reactions.
These
target-oriented
delivery
of
with
precision
site-specific,
mild
toxicity,
prolonged
circulation
time,
high
solubility,
long
retention
time
biological
system,
which
circumvent
problems
associated
conventional
approach.
Recently,
nanocarriers
such
as
dendrimers,
liposomes,
nanotubes,
nanoparticles
have
been
extensively
investigated
through
structural
characteristics,
size
manipulation,
selective
diagnosis
disease
imaging
molecules,
very
effective
introduce
new
paradigm
shift
drugs.
In
this
review,
use
nanomedicines
has
demonstrated
treating
various
diseases
significant
advances
applications
different
fields.
addition,
review
discusses
current
challenges
future
directions
for
research
these
promising
fields
well.
Journal of Materials Chemistry B,
Journal Year:
2023,
Volume and Issue:
11(23), P. 5051 - 5070
Published: Jan. 1, 2023
This
review
summarizes
the
synthesis
of
gold
nanoclusters
using
biomolecules
as
templates
and
their
applications
in
bioimaging,
disease
treatment
drug
delivery.
Journal of Materials Chemistry B,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Jan. 1, 2025
Photothermal
therapy
(PTT)
is
a
cutting-edge
technique
that
harnesses
light
energy
and
converts
it
into
heat
for
precise
tumor
ablation.
By
employing
photothermal
agents
to
selectively
generate
target
cancer
cells,
PTT
has
emerged
as
promising
treatment
strategy.
Notably,
therapies
conducted
in
the
second
near-infrared
(NIR-II)
window
exhibit
superior
therapeutic
outcomes,
owing
deeper
tissue
penetration
reduced
scattering.
In
this
study,
we
developed
biomimetic
NIR-II
aggregation-induced
emission
(AIE)
nanoparticles
(2TB-NPs@TM)
high-efficiency
imaging
targeted
phototherapy
of
ovarian
cancer.
The
core
nanoparticle
aggregates
(2TB-NPs)
display
strong
fluorescence
high
conversion
efficiency,
while
outer
cell
membrane
coating
facilitates
active
targeting
recognition
tissues.
This
design
imparts
excellent
biocompatibility
enhances
drug
delivery
leading
potent
synergistic
effects.
Our
findings
open
new
avenues
advancing
targeted,
high-performance
diagnostics
treatment.
Pharmaceutics,
Journal Year:
2025,
Volume and Issue:
17(3), P. 296 - 296
Published: Feb. 24, 2025
Melanoma,
a
highly
aggressive
form
of
skin
cancer,
poses
major
therapeutic
challenge
due
to
its
metastatic
potential,
resistance
conventional
therapies,
and
the
complexity
tumor
microenvironment
(TME).
Materials
science
nanotechnology
advances
have
led
using
nanocarriers
such
as
liposomes,
dendrimers,
polymeric
nanoparticles,
metallic
nanoparticles
transformative
solutions
for
precision
melanoma
therapy.
This
review
summarizes
findings
from
Web
Science,
PubMed,
EMBASE,
Scopus,
Google
Scholar
highlights
role
in
overcoming
treatment
barriers.
Nanoparticles
facilitate
passive
active
targeting
through
mechanisms
enhanced
permeability
retention
(EPR)
effect
functionalization
with
tumor-specific
ligands,
thereby
improving
accuracy
drug
delivery
reducing
systemic
toxicity.
Stimuli-responsive
systems
multi-stage
further
improve
overcome
challenges
poor
penetration
resistance.
Emerging
platforms
combine
diagnostic
imaging
delivery,
paving
way
personalized
medicine.
However,
there
are
still
issues
scalability,
biocompatibility,
regulatory
compliance.
comprehensive
potential
integrating
genetics
proteomics,
scalable,
patient-specific
therapies.
These
interdisciplinary
innovations
promise
redefine
provide
safer,
more
effective,
accessible
treatments.
Continued
research
is
essential
bridge
gap
between
evidence-based
scientific
clinical
applications.
Journal of Applied Polymer Science,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Feb. 24, 2025
ABSTRACT
Polymer‐drug
conjugates
(PDCs)
modify
the
biodistribution
of
small‐molecule
anticancer
agents
to
prevent
undesired
off‐target
adverse
effects.
Here,
we
report
preparation
two
PDCs
by
strain‐promoted
[3
+
2]
azide‐alkyne
cycloaddition‐mediated
step‐growth
polymerization.
This
method
does
not
require
use
a
catalyst
or
high
temperatures,
and
it
allows
rapid
synthesis
molecular‐weight
containing
gemcitabine
(M
w
~
40.18
kDa)
doxorubicin
1800
with
narrow
molecular
weight
distribution
drug
loading
(29.2
wt%
10.3wt%
doxorubicin).
α‐ω‐
bis
‐azide‐terminated
bifunctional
gemcitabine‐coupled
doxorubicin‐coupled
monomers,
linkage
via
Gly‐Phe‐Leu‐Gly
(GFLG),
cathepsin
B‐sensitive
peptide
linker,
were
separately
synthesized
polymerized
using
dibenzoazacyclooctyne
polyethylene
glycol
monomer.
Preliminary
in
vitro
evaluations
showed
B‐catalyzed
release
at
pH
5.0.
The
applied
for
syntheses
enables
selective
delivery
potent
agents.
